Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
| Status: | Archived |
|---|---|
| Conditions: | Pneumonia |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | August 2010 |
| End Date: | June 2011 |
A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM-101 Compared to Oral Levofloxacin in the Treatment of Patients With Community-Acquired Bacterial Pneumonia
Study to evaluate the safety and efficacy of oral CEM-101 compared to oral Levofloxacin in
the treatment of adults with moderate to moderately severe community-acquired bacterial
pneumonia.
Community-acquired bacterial pneumonia is an acute infection of the pulmonary parenchyma
with symptoms such as fever or hypothermia, chills, rigors, chest pain, and/or dyspnea. The
widespread emergence of antibiotic resistant pathogens, including the macrolide-resistant
Streptococcus pneumoniae, has resulted in a need for new and effective antibiotics that have
activity again CABP pathogens. CEM-101 is the first fluoroketolide with excellent in vitro
and in vivo activity against resistant S. pneumoniae and other key typical and atypical
bacterial respiratory pathogens.
We found this trial at
1
site
